Laura Pujols

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8956507/publications.pdf

Version: 2024-02-01

201385 243296 2,025 47 27 44 h-index citations g-index papers 51 51 51 2127 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Expression of glucocorticoid receptor \hat{l}_{\pm} - and \hat{l}_{\pm} -isoforms in human cells and tissues. American Journal of Physiology - Cell Physiology, 2002, 283, C1324-C1331.	2.1	185
2	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	1.4	110
3	Reduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma. Journal of Allergy and Clinical Immunology, 2011, 128, 66-72.e1.	1.5	106
4	Expression of the Human Glucocorticoid Receptor \hat{l}_{\pm} and \hat{l}^{2} Isoforms in Human Respiratory Epithelial Cells and Their Regulation by Dexamethasone. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 49-57.	1.4	104
5	A Short Course of Oral Prednisone Followed by Intranasal Budesonide Is an Effective Treatment of Severe Nasal Polyps. Laryngoscope, 2006, 116, 770-775.	1.1	91
6	Glucocorticoid receptors in human airways. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1042-1052.	2.7	86
7	Corticosteroid Treatment in Chronic Rhinosinusitis: The Possibilities and the Limits. Immunology and Allergy Clinics of North America, 2009, 29, 657-668.	0.7	86
8	United airways again: high prevalence of rhinosinusitis and nasal polyps in bronchiectasis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 790-797.	2.7	76
9	Glucocorticoid Receptor Isoforms \hat{l}_{\pm} and \hat{l}_{\pm}^2 inin VitroCytokine-induced Glucocorticoid Insensitivity. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 420-425.	2.5	65
10	Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 814-819.	1.5	62
11	Alpha and beta glucocorticoid receptors: Relevance in airway diseases. Current Allergy and Asthma Reports, 2007, 7, 93-99.	2.4	62
12	Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. Journal of Allergy and Clinical Immunology, 2002, 109, 824-830.	1.5	59
13	United airways: the impact of chronic rhinosinusitis and nasal polyps in bronchiectasic patient's quality of life. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1524-1529.	2.7	53
14	Oral plus nasal corticosteroids improve smell, nasal congestion, and inflammation in sinoâ€nasal polyposis. Laryngoscope, 2014, 124, 50-56.	1.1	52
15	Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1377-1386.	2.7	50
16	Expression of the glucocorticoid receptor alpha and beta isoforms in human nasal mucosa and polyp epithelial cells. Respiratory Medicine, 2003, 97, 90-96.	1.3	48
17	Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion. European Respiratory Journal, 1997, 10, 1489-1495.	3.1	46
18	Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 122-126.	2.7	45

#	Article	IF	CITATIONS
19	Low E-prostanoid 2 receptor levels and deficient induction of the IL- $1\hat{l}^2$ /IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2016, 137, 99-107.e7.	1.5	44
20	Expression of glucocorticoid receptors \hat{A} and \hat{A} in steroid sensitive and steroid insensitive interstitial lung diseases. Thorax, 2004, 59, 687-693.	2.7	43
21	The importance of smell in patients with bronchiectasis. Respiratory Medicine, 2011, 105, 44-49.	1.3	42
22	Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2004, 21, 35-42.	0.2	41
23	Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clinical and Experimental Allergy, 2006, 36, 52-58.	1.4	39
24	Lung Myofibroblasts Are Characterized by Down-Regulated Cyclooxygenase-2 and Its Main Metabolite, Prostaglandin E2. PLoS ONE, 2013, 8, e65445.	1.1	36
25	Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax, 2006, 61, 592-596.	2.7	35
26	Importance of glucocorticoid receptors in upper and lower airways. Frontiers in Bioscience - Landmark, 2010, 15, 789.	3.0	28
27	Low prostaglandin <scp>E₂</scp> and cyclooxygenase expression in nasal mucosa fibroblasts of aspirinâ€intolerant asthmatics. Respirology, 2013, 18, 711-717.	1.3	27
28	Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps. Laryngoscope, 2015, 125, E158-67.	1.1	27
29	Differential Expression of Remodeling Markers by Tissue Structure in Nasal Polyposis. American Journal of Rhinology and Allergy, 2013, 27, e69-e74.	1.0	26
30	Glucocorticoid Receptor in Human Respiratory Epithelial Cells. NeuroImmunoModulation, 2009, 16, 290-299.	0.9	24
31	Clinical and Biological Markers of Difficult-to-Treat Severe Chronic Rhinosinusitis. Current Allergy and Asthma Reports, 2015, 15, 19.	2.4	21
32	Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2. Journal of Inflammation, 2009, 6, 30.	1.5	20
33	Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 184-197.	1.3	19
34	Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respiratory Research, 2011, 12, 23.	1.4	17
35	Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment. Rhinology, 2006, 44, 8-13.	0.7	15
36	An intranasal selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite sensitive mice. Respiratory Research, 2008, 9, 72.	1.4	12

#	Article	IF	CITATIONS
37	Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo. European Respiratory Journal, 2009, 33, 502-508.	3.1	12
38	Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy, Asthma and Clinical Immunology, 2018, 14, 86.	0.9	12
39	Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects. Respiratory Medicine, 2011, 105, 218-225.	1.3	11
40	Signal Transduction Pathways (MAPKs, NF-κB, and C/EBP) Regulating COX-2 Expression in Nasal Fibroblasts from Asthma Patients with Aspirin Intolerance. PLoS ONE, 2012, 7, e51281.	1.1	11
41	Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma. PLoS ONE, 2015, 10, e0125443.	1.1	11
42	Relevance of COXâ€2 gene expression in dementia with lewy bodies associated with Alzheimer pathology. Movement Disorders, 2008, 23, 804-810.	2.2	9
43	Deficient glucocorticoid induction of anti-inflammatory genes in nasal polyp fibroblasts of asthmatic patients with and without aspirin intolerance. Journal of Allergy and Clinical Immunology, 2013, 132, 1243-1246.e12.	1.5	6
44	Fluticasone Furoate Inhibits Cytokine Secretion from Nasal Epithelial Cells and Reduces Eosinophil Survival in an in vitro Model of Eosinophilic Inflammation. International Archives of Allergy and Immunology, 2014, 163, 225-233.	0.9	6
45	Translocaci $ ilde{A}^3$ n nuclear del receptor de glucocorticoides en fibroblastos de pacientes asm $ ilde{A}_i$ ticos con poliposis nasal insensible al tratamiento glucocorticoideo. Archivos De Bronconeumologia, 2011, 47, 115-121.	0.4	4
46	Impact of cell culture methods on the outcomes of the in vitro inflammatory response in nasal polyps. Rhinology, 2011, 49, 562-569.	0.7	4
47	Nuclear Translocation of the Glucocorticoid Receptor in Fibroblasts of Asthmatic Patients with Nasal Polyposis Insensitive to Glucocorticoid Treatment. Archivos De Bronconeumologia, 2011, 47, 115-121.	0.4	1